GlassScriptPhysician profile
Joseph R O'Connell
NPI 1992733422
$7,650.06
in general payments reported to CMS, 2019-2025
52 companies · $838 in 2025
The $838 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $886 · 2020: $979 · 2021: $1,927 · 2022: $1,038 · 2023: $1,064 · 2024: $919 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,820.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,376.58 | 2021-2025 | |
| Pfizer INC. | $1,023.54 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $524.61 | 2019-2022 | |
| Glaxosmithkline, LLC. | $493.95 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $461.92 | 2019-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $442.28 | 2019-2024 | Dificid, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $321.99 | 2019-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $237.38 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $234.31 | 2019-2023 | Farxiga |
| Amgen INC. | $230.53 | 2020-2025 | Evenity |
| Biohaven Pharmaceuticals, INC. | $208.64 | 2021 | |
| Lilly USA, LLC | $179.53 | 2020-2024 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $165.13 | 2020-2021 | |
| Allergan, INC. | $149.17 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $130.22 | 2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph O'Connell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.